VitaDAO, a collective for community-governed drug development focusing on longevity research, raised USD 4.1 million in a strategic funding round that saw participation from Pfizer Ventures, Shine Capital, and L1 Digital among others. It's total funding following this round stands at USD 9.7 million.
It aims to use the fresh capital to invest in longevity research projects, precede the spinout of VitaDAO’s first biotech startups scheduled in Q1 2023, and commercialize and license its IP-NFT assets through its partnership with Molecule DAO .
The company reported that its community grew to over 9,000 researchers and contributors in 2022, and had distributed more than USD 3.5 million in funding to over 15 longevity-based research projects.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.